
Spineway S.A (ALSPW) | Financial Analysis & Statements
Spineway S.A. | Small-cap | Healthcare
Spineway S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
30.4M
Total Liabilities
6.2M
Shareholders Equity
24.2M
Debt to Equity
0.25
Cash Flow Metrics
Revenue & Profitability Trend
Spineway S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 12.0M | 10.5M | 7.4M | 4.3M | 3.4M |
Cost of Goods Sold | 3.5M | 2.6M | 1.4M | 826.0K | 412.1K |
Gross Profit | 8.5M | 7.9M | 6.0M | 3.5M | 3.0M |
Gross Margin % | 70.7% | 74.9% | 80.5% | 80.7% | 87.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | 1.8M | 2.1M |
Other Operating Expenses | 2.3M | 4.6M | 3.4M | 1.5M | 1.4M |
Total Operating Expenses | 2.3M | 4.6M | 3.4M | 3.3M | 3.5M |
Operating Income | -885.0K | -4.3M | -3.2M | -1.4M | -1.8M |
Operating Margin % | -7.4% | -40.6% | -42.9% | -32.9% | -51.9% |
Non-Operating Items | |||||
Interest Income | - | - | - | 329.7K | 52.5K |
Interest Expense | 93.0K | 66.0K | 38.0K | 49.0K | 12.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -3.9M | -6.5M | -3.1M | -1.6M | -14.0M |
Income Tax | - | - | 0 | 0 | -231.6K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -3.9M | -6.5M | -3.1M | -1.6M | -13.6M |
Net Margin % | -32.3% | -61.9% | -42.2% | -36.9% | -402.1% |
Key Metrics | |||||
EBITDA | -1.1M | -3.4M | -2.0M | -252.0K | -918.1K |
EPS (Basic) | €0.00 | €-0.82 | €0.00 | €-0.20 | €-48,193.74 |
EPS (Diluted) | €0.00 | €-0.82 | €0.00 | €-0.20 | €-48,193.74 |
Basic Shares Outstanding | 145792276 | 7972 | 11451540 | 196 | 282 |
Diluted Shares Outstanding | 145792276 | 7972 | 11451540 | 196 | 282 |
Income Statement Trend
Spineway S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 4.5M | 1.8M | 5.5M | 13.9M | 4.8M |
Short-term Investments | - | - | - | 5.0M | - |
Accounts Receivable | 3.2M | 2.7M | 2.0M | 1.7M | 1.1M |
Inventory | 4.7M | 4.4M | 3.9M | 2.4M | 1.9M |
Other Current Assets | 1.0K | - | 1.0K | - | - |
Total Current Assets | 13.9M | 10.2M | 12.1M | 18.6M | 8.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 5.9M | 5.5M | 4.7M | 6.1M | 0 |
Goodwill | 9.5M | 14.7M | 14.7M | 2.6M | 1.3M |
Intangible Assets | - | 3.9M | 3.9M | 1.5M | 1.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.0K | 1.0K | 1.0K | 24.8K | 297.4K |
Total Non-Current Assets | 16.5M | 16.2M | 15.6M | 6.9M | 6.6M |
Total Assets | 30.4M | 26.3M | 27.7M | 25.6M | 14.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 984.0K | 1.6M | 2.5M | 1.2M | 823.5K |
Short-term Debt | 153.0K | 484.0K | 772.0K | 1.1M | 359.4K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 655.0K | 97.0K | 1.5M | 863.0K | -90 |
Total Current Liabilities | 4.2M | 4.9M | 2.5M | 2.1M | 1.7M |
Non-Current Liabilities | |||||
Long-term Debt | 1.7M | 2.1M | 2.9M | 2.4M | 2.7M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | 1.0K | -1.0K | 1.0K | 1.0K |
Total Non-Current Liabilities | 1.9M | 2.4M | 3.2M | 2.6M | 3.0M |
Total Liabilities | 6.2M | 7.3M | 5.7M | 4.7M | 4.7M |
Equity | |||||
Common Stock | 58.0K | 286.0K | 182.0K | 1.6M | 463.3K |
Retained Earnings | -3.9M | -6.5M | -3.1M | -1.6M | -13.6M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 24.2M | 19.1M | 22.0M | 20.9M | 10.2M |
Key Metrics | |||||
Total Debt | 1.8M | 2.6M | 3.7M | 3.5M | 3.1M |
Working Capital | 9.7M | 5.3M | 9.6M | 16.5M | 6.6M |
Balance Sheet Composition
Spineway S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -3.9M | -6.5M | -3.1M | -1.6M | -685.0K |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 0 | -1.3M | 140.0K | -668.0K | 0 |
Operating Cash Flow | -3.9M | -6.9M | -3.1M | -2.5M | -685.0K |
Investing Activities | |||||
Capital Expenditures | - | -794.0K | - | - | 0 |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | -582.0K | -50.0K |
Investment Sales | - | - | - | 0 | 2.0K |
Investing Cash Flow | - | -724.0K | -10.2M | -1.2M | -48.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | 1.5M | 288.0K | 24.8M | 12.6M |
Debt Repayment | - | -808.0K | -5.1M | -298.0K | -13.5M |
Financing Cash Flow | - | 3.5M | 3.6M | 10.7M | 872.0K |
Free Cash Flow | -3.3M | -7.3M | -1.6M | -1.8M | -1.3M |
Net Change in Cash | -3.9M | -4.1M | -9.7M | 7.0M | 139.0K |
Cash Flow Trend
Spineway S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
0.02
Forward P/E
4.26
Price to Book
0.18
Price to Sales
0.38
PEG Ratio
4.26
Profitability Ratios
Profit Margin
-16.10%
Operating Margin
-20.87%
Return on Equity
-8.42%
Return on Assets
-2.79%
Financial Health
Current Ratio
3.18
Debt to Equity
6.46
Beta
0.80
Per Share Data
EPS (TTM)
€0.00
Book Value per Share
€0.70
Revenue per Share
€0.51
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alspw | 4.5M | 0.02 | 0.18 | -8.42% | -16.10% | 6.46 |
EssilorLuxottica | 123.5B | 51.90 | 3.26 | 6.44% | 8.74% | 36.58 |
Sartorius Stedim | 17.3B | 76.84 | 4.40 | 5.69% | 7.78% | 73.51 |
Crossject S.A | 85.4M | - | - | 478.68% | 0.00% | -7.88 |
Visiomed Group SA | 53.2M | 57.80 | 2.10 | 3.68% | 6.58% | 32.03 |
Bonyf N.V | 7.8M | - | 17.50 | -1.38% | 8.02% | 0.00 |
Financial data is updated regularly. All figures are in the company's reporting currency.